1Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study[J]. Brain, 2000,123(11):2297-2305.
2Obeso JA, Rodriguez-Oroz MC,Chana R, et al. The evolution and origin of motor complications in Parkinson's disease[J]. Neurology, 2000, 55(11 suppl 4):S13-20.
3Rodriguez M, DeLong MR. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease:problems with current models of the basal ganglia[J].Ann Neurol, 2000,47 : 22-34.
4Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease[J]. Neurology, 2004, 62(1 Suppl 1):S56-63.
5Olanow W, Schapira AH, Raseol O. Continuous dopamine-receptor stimulation in early Parkinson' s disease[J]. Trends Neurosci, 2000,23(10suppl) :Sl17-126.
6Koller WC, Hutton JT, Tolosa E. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study [ J ]. Neurologyo,1999,53(5): 1012-1019.
7Przuntek H o Conrad B,Dichgans J. et al. SELEDO, a 5-year long-term trial on the effect of selegeline in early Parkinsonian patients treated with levodopa[J]. Eur J Neurol, 1999,6(2):141-150.
8Poewe W. The role of COMT inhibition in the treatment of Parkinson' s disease[J]. Neurologyo 2004,62(1 Suppl 1):S31-38.
9Sit SY. Dopamine agonists in the treatment of Parkinson's disease past, present and future[J].Curr Pharm Des,2000,6(12) :1211-1248.
10LeWitt PA, Nyholm D. New developments in levodopa therapy[J]. Neurology,2004,62(Suppl 1):S9-16.
